News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Awesome bounce from the $56.50 offering price. Called that one. 
$ASPX DD Notes ~ http://www.ddnotesmaker.com/ASPX
bullish
quick trade
$ASPX recent news/filings
## source: finance.yahoo.com
Wed, 17 Dec 2014 17:00:00 GMT ~ ASPX: Auspex Pharma Hits A Homerun In Phase 3 Huntington's Chorea Trial
read full: http://finance.yahoo.com/news/aspx-auspex-pharma-hits-homerun-170000838.html
*********************************************************
Tue, 16 Dec 2014 21:27:02 GMT ~ AUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exh
read full: http://biz.yahoo.com/e/141216/aspx8-k.html
*********************************************************
Tue, 16 Dec 2014 21:14:50 GMT ~ Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease
[at noodls] - Pivotal Phase 3 Trial Met Primary and Multiple Key Secondary Efficacy Endpoints; Favorable Safety and Tolerability Demonstrated ARC-HD Trial Shows Successful Maintenance of Chorea Control After Switch ...
read full: http://www.noodls.com/view/5691904A85D1537C3A81BFF0F3DC9584E734EE06
*********************************************************
Tue, 16 Dec 2014 21:06:00 GMT ~ Auspex Drug Reduces Uncontrolled Movements in Huntington's Patients
read full: http://www.thestreet.com/story/12986308/1/auspex-drug-reduces-uncontrolled-movements-in-huntingtons-patients.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
Tue, 16 Dec 2014 21:05:00 GMT ~ Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease
[GlobeNewswire] - Pivotal Phase 3 Trial Met Primary and Multiple Key Secondary Efficacy Endpoints; Favorable Safety and Tolerability Demonstrated ARC-HD Trial Shows Successful Maintenance of Chorea Control After Switch ...
read full: http://finance.yahoo.com/news/auspex-announces-positive-topline-results-210500624.html
*********************************************************
$ASPX charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ASPX company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ASPX/company-info
Ticker: $ASPX
OTC Market Place: Not Available
CIK code: not found
Company name: Auspex Pharmaceuticals, Inc.
Incorporated In:
$ASPX share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$ASPX extra dd links
Company name: Auspex Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ASPX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ASPX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ASPX+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ASPX/news - http://finance.yahoo.com/q/h?s=ASPX+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ASPX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ASPX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ASPX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ASPX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Auspex+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Auspex+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Auspex+Pharmaceuticals%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ASPX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ASPX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ASPX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ASPX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ASPX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ASPX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ASPX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ASPX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ASPX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ASPX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ASPX+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ASPX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ASPX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ASPX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ASPX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ASPX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ASPX/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ASPX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ASPX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ASPX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ASPX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ASPX
$ASPX DD Notes ~ http://www.ddnotesmaker.com/ASPX
|
Followers
|
1
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
29
|
|
Created
|
12/17/14
|
Type
|
Free
|
| Moderators | |||
Pratik Shah is President and CEO of Auspex. He was previously Executive Chairman of Auspex and has been involved in shaping the company's strategy since joining the board in 2007. He has been involved in a number of biotechnology companies and was lead director and founding investor in CNS Therapeutics (acquired by Mallincrodt). He represents Thomas, McNerney & Partners as a Partner on the boards of Cebix, Ocera Therapeutics, Inc. and SGB. Pratik was co-founder of biopharmaceutical company Kalypsys, Inc. Before co-founding Kalypsys, Pratik was at McKinsey & Company (San Francisco), where he focused on biotechnology and venture capital projects. He was formerly co-founder and VP of Operations at NephRx Corporation, a start-up company focused on the discovery of therapeutic proteins for renal disease. Pratik holds a BS in Biological Sciences from the University of California at Irvine and both a PhD in Biochemistry & Molecular Biology and an MBA in Finance from the University of Chicago.
John Schmid joined us as Chief Financial Officer in September 2013. Before joining us, Mr. Schmid co- founded Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, where he served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. in September 2013. Prior to Trius Therapeutics, Inc., Mr. Schmid served as the Chief Financial Officer at GeneFormatics, Inc., a private biotechnology company, from 1998 to 2003 and Endonetics, Inc., a private medical device company, from 1995 to 1998. Mr. Schmid also currently serves as the chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. Mr. Schmid holds a BA in Economics from Wesleyan University and an MBA from the University of San Diego.
Dr. Stamler has served as our Chief Medical Officer since January 2011. Prior to joining us, Dr. Stamler served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., a publicly-traded biopharmaceutical company, from 2008 to 2010 and Chief Scientific Officer and Head of Drug Development at Prestwick Pharmaceuticals, Inc., a private pharmaceutical company, from 2005 to 2008. Prior to Prestwick Pharmaceuticals, Inc., Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries from 1997 to 2005, in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc. from 2003 to 2005 and as Vice President, Clinical Research Center at Fujisawa Research Institute of America from 2000 to 2003. Dr. Stamler began his career at Abbott Laboratories, a publicly-traded global pharmaceuticals and healthcare products company, where he served in various positions from 1993 to 1997, including Director of Clinical Research, Pharmaceutical Products for the International Division. Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a BA in Biology from the University of Chicago.
Sam Saks is a board certified oncologist who was most recently the founding CEO of Jazz Pharmaceuticals until his retirement in 2009. From 2001 until he joined Jazz, Dr. Saks was company group chairman of ALZA Corporation and member of the Johnson & Johnson Pharmaceutical Operating Committee. From 1992 until 2001, he held executive positions at ALZA, including group vice president, ALZA Pharmaceuticals, where he was responsible for clinical, regulatory and commercial activities. Prior to joining ALZA, Dr. Saks held clinical research and development management positions with Schering-Plough, Xoma and Genentech. Dr. Saks has a Bachelor's degree in biology and his medical degree from the University of Illinois. He completed his residency in internal medicine at Texas Southwestern, and his fellowship in oncology at the University of California – San Francisco, and is Board certified in both specialties. Dr. Saks is a director of Auspex Pharmaceuticals, TONIX Pharmaceuticals, Depomed, Bullet Biotechnology, NuMedii and Velocity Pharmaceutical Development.
Dr. Chowrira joined us as Chief Operating Officer in October 2013. Prior to joining us, Dr. Chowrira served as President and Chief Executive Officer of Addex Therapeutics, Inc., a biotechnology company publicly-traded on the SIX Swiss Exchange, from August 2011 to May 2013. Prior to Addex Therapeutics, Inc., he served as Senior Vice President and Chief Operating Officer at Nektar Therapeutics, or Nektar, a publicly-traded clinical-stage biopharmaceutical company, from May 2008 to January 2011, during which time he also served as the chairman of the board of directors of Nektar India PTY Ltd., a wholly owned subsidiary of Nektar. Prior to Nektar, Dr. Chowrira served as the Vice President, Legal and Chief Patent Counsel at Sirna Therapeutics, Inc., a publicly-traded biotechnology company, from June 2003 until its acquisition by Merck & Co., Inc., or Merck, a publicly-traded global health care company, in December 2006, after which he stayed at Merck until May 2008 as Vice President, Sirna and Executive Director, Worldwide Licensing. From 1993 to 2003, Dr. Chowrira held various leadership positions at Sirna Therapeutics, Inc.'s predecessor, Ribozyme Pharmaceuticals, Inc., a publicly-traded biotechnology company. Dr. Chowrira received a JD from the University of Denver—Sturm College of Law, a PhD in Molecular Biology from the University of Vermont College of Medicine, an MS in Molecular Biology from Illinois State University and a BS in Microbiology from the University of Agricultural Sciences, Bangalore, India.
Dr. Sommer joined us as Chief Operating Officer in 2009 and became our Vice President in October 2013. Prior to joining us, Dr. Sommer served as Senior Vice President—Research and then President and Chief Executive Officer of Celtrix Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from 1995 until it was acquired by Insmed, Inc., a biopharmaceutical company, in 2000. From 2000 to 2007, Dr. Sommer served as Chief Scientific Officer of Insmed. Prior to Celtrix Pharmaceuticals, Inc., he began his career as Vice President, Research and Development at BioGrowth, Inc., a private biotechnology company, in 1989. Dr. Sommer received his PhD in Microbiology from the University of California, Davis and an MS/BS in Technical Microbiology from the Swiss Federal Institute of Technology.
